News

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.

06/06/2025

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.

05/09/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Soligenix, Inc. (SNGX) a buy, sell, or hold?

Soligenix, Inc. (SNGX) can hold. Click on Rating Page for detail.

What is Soligenix, Inc.'s stock price?

The price of Soligenix, Inc. (SNGX) is 1.26 and it was updated on 2025-07-03 01:03:06.

Is Soligenix, Inc. (SNGX) overvalued or undervalued?

Currently Soligenix, Inc. (SNGX) is in undervalued.

News

From:

To:

News
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL). Mon, Apr. 14, 2025
IBN Initiates Coverage of Soligenix Inc. AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. Tue, Mar. 25, 2025
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of CiVax™, a thermostabilized subunit vaccine against SARS-CoV-2. Tue, Mar. 25, 2025
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024. Fri, Mar. 21, 2025
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J. , March 6, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its lead investigators for the cutaneous T-cell lymphoma (CTCL) and psoriasis programs are presenting findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the treatment of CTCL and SGX302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis. Thu, Mar. 06, 2025

SEC Filings

SEC Filings
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/28/2025
Soligenix, Inc. (SNGX) - POS AM SEC Filings 03/21/2025
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/21/2025
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/10/2025
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/13/2024
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/08/2024
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/08/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/11/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/16/2024
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 08/16/2024
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/09/2024
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/09/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/25/2024
Soligenix, Inc. (SNGX) - S-1 SEC Filings 07/24/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/09/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/31/2024
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/29/2024
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/28/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/24/2024
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/22/2024
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/17/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/17/2024
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/15/2024
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/10/2024
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/10/2024
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 04/29/2024
Soligenix, Inc. (SNGX) - ARS SEC Filings 04/29/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/22/2024
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 04/19/2024
Soligenix, Inc. (SNGX) - 424B4 SEC Filings 04/19/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/03/2024
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 04/02/2024
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 03/15/2024
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/15/2024
Soligenix, Inc. (SNGX) - S-1 SEC Filings 01/16/2024
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/22/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/15/2023
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/15/2023
Soligenix, Inc. (SNGX) - S-3/A SEC Filings 12/08/2023
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/08/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/17/2023
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/13/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/20/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 10/17/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 10/16/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 10/13/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 10/12/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 09/22/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/22/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 09/15/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/15/2023
Soligenix, Inc. (SNGX) - S-3 SEC Filings 08/30/2023
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/21/2023
Soligenix, Inc. (SNGX) - NT 10-Q - Quarterly Report SEC Filings 08/14/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/07/2023
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/07/2023
Soligenix, Inc. (SNGX) - ARS SEC Filings 08/07/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/07/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/23/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/26/2023
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/15/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/09/2023
Soligenix, Inc. (SNGX) - 424B4 SEC Filings 05/08/2023
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/05/2023
Soligenix, Inc. (SNGX) - 3 SEC Filings 05/05/2023
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 05/04/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/03/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/01/2023
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 04/20/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/19/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/14/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/10/2023
Soligenix, Inc. (SNGX) - S-1 SEC Filings 03/31/2023
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/31/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/24/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/14/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/09/2023
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 01/11/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/11/2023
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 01/06/2023
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/27/2022
Soligenix, Inc. (SNGX) - 8-A12G SEC Filings 12/27/2022
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 12/23/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/23/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/19/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/15/2022
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/09/2022
Soligenix, Inc. (SNGX) - 4 SEC Filings 11/21/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/18/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 11/16/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 11/15/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 11/14/2022
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/10/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 11/09/2022
Soligenix, Inc. (SNGX) - S-8 SEC Filings 10/28/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/27/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/25/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/20/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 10/05/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/23/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 09/13/2022
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/12/2022
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/09/2022
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/05/2022
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 07/26/2022
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 07/25/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/13/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/12/2022
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/18/2022
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/13/2022
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/29/2022
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/21/2022
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/04/2022
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/23/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/20/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/15/2021
Soligenix, Inc. (SNGX) - 25-NSE SEC Filings 12/15/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/14/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/10/2021
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/12/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/29/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/24/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/24/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/20/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/17/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/27/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/13/2021
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 08/13/2021
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/13/2021
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/10/2021
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/10/2021
Soligenix, Inc. (SNGX) - NT 10-Q - Quarterly Report SEC Filings 05/18/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/18/2021
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/18/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/07/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/13/2021
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/30/2021
Soligenix, Inc. (SNGX) - EFFECT SEC Filings 01/29/2021
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 01/27/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/26/2021
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 01/22/2021
Soligenix, Inc. (SNGX) - S-3 SEC Filings 01/15/2021
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/04/2021
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/22/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/16/2020
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/11/2020
Soligenix, Inc. (SNGX) - 8-K/A - Current report SEC Filings 12/03/2020
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 11/25/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/25/2020
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/12/2020
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 11/06/2020
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 10/23/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/18/2020
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/18/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/10/2020
Soligenix, Inc. (SNGX) - EFFECT SEC Filings 08/28/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/28/2020
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 08/28/2020
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 08/26/2020
Soligenix, Inc. (SNGX) - S-3/A SEC Filings 08/14/2020
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/14/2020
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/13/2020
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/07/2020
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/07/2020
Soligenix, Inc. (SNGX) - S-3/A SEC Filings 07/31/2020
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 07/31/2020
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 07/24/2020
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 07/24/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/20/2020
Soligenix, Inc. (SNGX) - S-3 SEC Filings 07/17/2020
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/19/2020
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/15/2020
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 05/06/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/30/2020
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 04/23/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/13/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/10/2020
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 04/10/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/03/2020
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/30/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/20/2020
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 03/20/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/19/2020
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/07/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/14/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/03/2020
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/02/2020
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/17/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/13/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 11/19/2019
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/12/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/18/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/23/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/17/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/11/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/11/2019
Soligenix, Inc. (SNGX) - 3 SEC Filings 09/11/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/10/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/29/2019
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/13/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/31/2019
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 07/26/2019
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 07/26/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/10/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/09/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/08/2019
Soligenix, Inc. (SNGX) - 3 SEC Filings 07/08/2019
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/14/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/23/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 04/22/2019
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/26/2019
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/15/2019
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/13/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/04/2019
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/14/2018
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/09/2018
Soligenix, Inc. (SNGX) - 4 SEC Filings 10/18/2018
Soligenix, Inc. (SNGX) - 4 SEC Filings 10/17/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/15/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/03/2018
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 10/03/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/28/2018
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/28/2018
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/22/2018
Soligenix, Inc. (SNGX) - DEFR14A SEC Filings 08/17/2018
Soligenix, Inc. (SNGX) - 10-K/A - Current report SEC Filings 08/17/2018
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/10/2018
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/10/2018
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/08/2018
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 07/31/2018
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 07/30/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/25/2018
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/25/2018
Soligenix, Inc. (SNGX) - 3 SEC Filings 07/25/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/19/2018
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 07/09/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/02/2018
Soligenix, Inc. (SNGX) - 424B4 SEC Filings 06/29/2018
Soligenix, Inc. (SNGX) - EFFECT SEC Filings 06/27/2018
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 06/20/2018
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 06/18/2018
Soligenix, Inc. (SNGX) - S-1 SEC Filings 05/25/2018
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/11/2018
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/15/2018
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/13/2018
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/25/2018
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/11/2017
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 12/01/2017
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/01/2017
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/30/2017
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 11/28/2017
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 11/28/2017
Soligenix, Inc. (SNGX) - S-1 SEC Filings 11/20/2017
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 11/13/2017
Soligenix, Inc. (SNGX) - D SEC Filings 11/08/2017
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 11/07/2017
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/06/2017
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/31/2017
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 10/31/2017
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 10/12/2017
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/11/2017
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/29/2017
Soligenix, Inc. (SNGX) - 424B5 SEC Filings 08/11/2017
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/11/2017
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 08/09/2017
Soligenix, Inc. (SNGX) - S-3/A SEC Filings 08/08/2017
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 06/16/2017
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/14/2017
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/12/2017
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 05/26/2017
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 05/18/2017
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 05/16/2017
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/11/2017
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 05/08/2017
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/08/2017
Soligenix, Inc. (SNGX) - S-3 SEC Filings 05/05/2017
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 04/28/2017
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 04/28/2017
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/26/2017
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 04/18/2017
Soligenix, Inc. (SNGX) - 4 SEC Filings 04/04/2017
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/27/2017
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/23/2017
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/18/2017
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/20/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/16/2016
Soligenix, Inc. (SNGX) - 424B4 SEC Filings 12/14/2016
Soligenix, Inc. (SNGX) - S-1MEF SEC Filings 12/13/2016
Soligenix, Inc. (SNGX) - CERTNAS SEC Filings 12/12/2016
Soligenix, Inc. (SNGX) - 8-A12B SEC Filings 12/12/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/08/2016
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 11/22/2016
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 11/22/2016
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 11/21/2016
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 11/16/2016
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 11/15/2016
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 11/15/2016
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 11/14/2016
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/14/2016
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/10/2016
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 10/17/2016
Soligenix, Inc. (SNGX) - S-1 SEC Filings 10/07/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/07/2016
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 09/19/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/12/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/12/2016
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/11/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/22/2016
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/22/2016
Soligenix, Inc. (SNGX) - 3 SEC Filings 06/22/2016
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/20/2016
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/13/2016
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/12/2016
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/02/2016
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 05/02/2016
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/29/2016
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 04/26/2016
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/26/2016
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 04/21/2016
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/14/2016
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 04/13/2016
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/13/2016
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/13/2016
Soligenix, Inc. (SNGX) - S-1 SEC Filings 04/08/2016
Soligenix, Inc. (SNGX) - POS AM SEC Filings 03/31/2016
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/24/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/07/2016
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/07/2016
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/04/2016
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/23/2015
Soligenix, Inc. (SNGX) - S-8 SEC Filings 12/14/2015
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/12/2015
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/12/2015
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/31/2015
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 08/21/2015
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 08/21/2015
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 08/20/2015
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/19/2015
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/12/2015
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/12/2015
Soligenix, Inc. (SNGX) - S-1 SEC Filings 08/03/2015
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/31/2015
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/01/2015
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/19/2015
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/19/2015
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 06/09/2015
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/03/2015
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/15/2015
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/14/2015
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/01/2015
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 05/01/2015
Soligenix, Inc. (SNGX) - 4 SEC Filings 04/09/2015
Soligenix, Inc. (SNGX) - POS AM SEC Filings 03/27/2015
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/25/2015
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/07/2015
Soligenix, Inc. (SNGX) - POS AM SEC Filings 12/29/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 12/29/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/24/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/24/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/19/2014
Soligenix, Inc. (SNGX) - 424B4 SEC Filings 12/19/2014
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 12/17/2014
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 12/17/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/10/2014
Soligenix, Inc. (SNGX) - 3 SEC Filings 12/10/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/08/2014
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 11/17/2014
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 11/17/2014
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 11/14/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/10/2014
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/10/2014
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 11/04/2014
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 11/04/2014
Soligenix, Inc. (SNGX) - S-1 SEC Filings 10/31/2014
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 10/16/2014
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 10/14/2014
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 10/03/2014
Soligenix, Inc. (SNGX) - S-1 SEC Filings 09/30/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/23/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/08/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/05/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/11/2014
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/11/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/05/2014
Soligenix, Inc. (SNGX) - S-8 SEC Filings 06/20/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/20/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/20/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/19/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/16/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/15/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/14/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/14/2014
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/12/2014
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/08/2014
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 05/08/2014
Soligenix, Inc. (SNGX) - POS AM SEC Filings 05/05/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/21/2014
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/08/2014
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/26/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 01/22/2014
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 01/16/2014
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 01/13/2014
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/08/2014
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/08/2014
Soligenix, Inc. (SNGX) - 3 SEC Filings 01/08/2014
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 12/30/2013
Soligenix, Inc. (SNGX) - S-1 SEC Filings 12/17/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/10/2013
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/09/2013
Soligenix, Inc. (SNGX) - 3 SEC Filings 12/09/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/21/2013
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/12/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/05/2013
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 10/21/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/18/2013
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 10/11/2013
Soligenix, Inc. (SNGX) - 4 SEC Filings 10/01/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/30/2013
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 09/30/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/27/2013
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/27/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/24/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/21/2013
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/14/2013
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/12/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/02/2013
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 06/26/2013
Soligenix, Inc. (SNGX) - POS AM SEC Filings 06/26/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/26/2013
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/26/2013
Soligenix, Inc. (SNGX) - 3 SEC Filings 06/26/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/24/2013
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/24/2013
Soligenix, Inc. (SNGX) - 424B4 SEC Filings 06/21/2013
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 06/20/2013
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 06/19/2013
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 06/19/2013
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 06/19/2013
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 06/13/2013
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 06/12/2013
Soligenix, Inc. (SNGX) - 10-K/A - Current report SEC Filings 06/12/2013
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 05/29/2013
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 05/28/2013
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 05/16/2013
Soligenix, Inc. (SNGX) - SC 13D SEC Filings 05/09/2013
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 05/08/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/08/2013
Soligenix, Inc. (SNGX) - D SEC Filings 05/03/2013
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/03/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/01/2013
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 03/01/2013
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 02/28/2013
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 02/26/2013
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 01/17/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/10/2013
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 01/02/2013
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/27/2012
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/21/2012
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 11/20/2012
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/14/2012
Soligenix, Inc. (SNGX) - S-1 SEC Filings 11/05/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/10/2012
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/10/2012
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/25/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/27/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/22/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/15/2012
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/14/2012
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 05/11/2012
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 05/11/2012
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 04/17/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/17/2012
Soligenix, Inc. (SNGX) - 4 SEC Filings 04/11/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/05/2012
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/27/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/17/2012
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 02/13/2012
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 02/07/2012
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/01/2012
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 01/30/2012
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 01/20/2012
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/18/2012
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 12/23/2011
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 12/07/2011
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 12/05/2011
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/02/2011
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/21/2011
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/14/2011
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 09/16/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/15/2011
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 09/15/2011
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 09/01/2011
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/19/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/12/2011
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/12/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/28/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/14/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/28/2011
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/24/2011
Soligenix, Inc. (SNGX) - 3 SEC Filings 06/24/2011
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/03/2011
Soligenix, Inc. (SNGX) - 3 SEC Filings 06/03/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/02/2011
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/17/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/13/2011
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/13/2011
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 05/10/2011
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/14/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/14/2011
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/30/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/29/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/02/2011
Soligenix, Inc. (SNGX) - 4 SEC Filings 02/02/2011
Soligenix, Inc. (SNGX) - 3 SEC Filings 02/02/2011
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 01/13/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/06/2011
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/16/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/16/2010
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/12/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/28/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 10/01/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/27/2010
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/27/2010
Soligenix, Inc. (SNGX) - 3 SEC Filings 09/27/2010
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 09/07/2010
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 09/02/2010
Soligenix, Inc. (SNGX) - 8-K/A - Current report SEC Filings 09/02/2010
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 08/30/2010
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 08/25/2010
Soligenix, Inc. (SNGX) - 8-K/A - Current report SEC Filings 08/25/2010
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 08/24/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/24/2010
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 08/20/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/20/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/20/2010
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/20/2010
Soligenix, Inc. (SNGX) - 3 SEC Filings 08/20/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/13/2010
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/13/2010
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/11/2010
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/11/2010
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 07/21/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 07/13/2010
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 07/12/2010
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 07/09/2010
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 07/09/2010
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 07/02/2010
Soligenix, Inc. (SNGX) - D SEC Filings 07/02/2010
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 06/28/2010
Soligenix, Inc. (SNGX) - S-1 SEC Filings 06/25/2010
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/22/2010
Soligenix, Inc. (SNGX) - 4 SEC Filings 06/21/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/18/2010
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 05/18/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/18/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/17/2010
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/14/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/10/2010
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/30/2010
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/28/2010
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/22/2010
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/20/2010
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/01/2010
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/31/2010
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/19/2010
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 01/12/2010
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 11/30/2009
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/23/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/13/2009
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/13/2009
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 11/12/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 11/12/2009
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 10/20/2009
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 10/19/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/19/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 10/13/2009
Soligenix, Inc. (SNGX) - 3 SEC Filings 10/13/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/09/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 10/08/2009
Soligenix, Inc. (SNGX) - S-1 SEC Filings 10/07/2009
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 10/02/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/01/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/30/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/29/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/28/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/22/2009
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/21/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/14/2009
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/14/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/11/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/09/2009
Soligenix, Inc. (SNGX) - 3 SEC Filings 07/09/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/07/2009
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 07/02/2009
Soligenix, Inc. (SNGX) - 3 SEC Filings 07/02/2009
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/18/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/15/2009
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/15/2009
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/14/2009
Soligenix, Inc. (SNGX) - POS AM SEC Filings 04/27/2009
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 04/24/2009
Soligenix, Inc. (SNGX) - DEFR14A SEC Filings 04/17/2009
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/17/2009
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 04/16/2009
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/15/2009
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 04/14/2009
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 04/02/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/31/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 03/30/2009
Soligenix, Inc. (SNGX) - 3 SEC Filings 03/30/2009
Soligenix, Inc. (SNGX) - 10-K - Current report SEC Filings 03/30/2009
Soligenix, Inc. (SNGX) - D SEC Filings 03/24/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/16/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 03/16/2009
Soligenix, Inc. (SNGX) - 3 SEC Filings 03/16/2009
Soligenix, Inc. (SNGX) - CT ORDER SEC Filings 03/04/2009
Soligenix, Inc. (SNGX) - D SEC Filings 02/27/2009
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 02/25/2009
Soligenix, Inc. (SNGX) - SC 13D SEC Filings 02/20/2009
Soligenix, Inc. (SNGX) - S-1 SEC Filings 02/13/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 02/13/2009
Soligenix, Inc. (SNGX) - D SEC Filings 02/03/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/21/2009
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/16/2009
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/19/2008
Soligenix, Inc. (SNGX) - D SEC Filings 12/05/2008
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 12/03/2008
Soligenix, Inc. (SNGX) - 3 SEC Filings 12/03/2008
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/01/2008
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/14/2008
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 11/14/2008
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/15/2008
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 08/14/2008
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/16/2008
Soligenix, Inc. (SNGX) - 10-Q - Quarterly Report SEC Filings 05/15/2008
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/29/2008
Soligenix, Inc. (SNGX) - 10KSB/A SEC Filings 04/29/2008
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/11/2008
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/02/2008
Soligenix, Inc. (SNGX) - S-1/A SEC Filings 04/01/2008
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 03/31/2008
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/27/2008
Soligenix, Inc. (SNGX) - 10KSB SEC Filings 03/27/2008
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 02/28/2008
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 02/15/2008
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/14/2008
Soligenix, Inc. (SNGX) - S-1 SEC Filings 02/14/2008
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/13/2008
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/28/2007
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 11/19/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/14/2007
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 11/14/2007
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 10/24/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/19/2007
Soligenix, Inc. (SNGX) - 4 SEC Filings 10/01/2007
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/29/2007
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/22/2007
Soligenix, Inc. (SNGX) - 4/A SEC Filings 08/22/2007
Soligenix, Inc. (SNGX) - DEFA14A SEC Filings 08/17/2007
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/17/2007
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 08/15/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/14/2007
Soligenix, Inc. (SNGX) - 4 SEC Filings 08/14/2007
Soligenix, Inc. (SNGX) - 3/A SEC Filings 08/14/2007
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 08/07/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/06/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/20/2007
Soligenix, Inc. (SNGX) - SC 13D SEC Filings 07/02/2007
Soligenix, Inc. (SNGX) - 4 SEC Filings 07/02/2007
Soligenix, Inc. (SNGX) - 3 SEC Filings 07/02/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/29/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 06/22/2007
Soligenix, Inc. (SNGX) - 8-A12G SEC Filings 06/22/2007
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 05/29/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/29/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/16/2007
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 05/15/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/11/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/04/2007
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/19/2007
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/17/2007
Soligenix, Inc. (SNGX) - SB-2/A SEC Filings 04/16/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/12/2007
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 03/26/2007
Soligenix, Inc. (SNGX) - AW SEC Filings 03/14/2007
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 03/13/2007
Soligenix, Inc. (SNGX) - POS AM SEC Filings 03/13/2007
Soligenix, Inc. (SNGX) - SB-2/A SEC Filings 03/12/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/12/2007
Soligenix, Inc. (SNGX) - SB-2 SEC Filings 03/09/2007
Soligenix, Inc. (SNGX) - 10KSB SEC Filings 03/09/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/07/2007
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 02/26/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/23/2007
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 02/16/2007
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/14/2007
Soligenix, Inc. (SNGX) - 4 SEC Filings 02/13/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/12/2007
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/09/2007
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 02/05/2007
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/30/2007
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 01/25/2007
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 01/19/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/19/2007
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 01/12/2007
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/04/2007
Soligenix, Inc. (SNGX) - DEFR14A SEC Filings 12/29/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/29/2006
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 12/18/2006
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 12/12/2006
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 12/11/2006
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 12/07/2006
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 12/05/2006
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 12/01/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/14/2006
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 11/14/2006
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 10/03/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/02/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/28/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/22/2006
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 09/19/2006
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 09/08/2006
Soligenix, Inc. (SNGX) - 3 SEC Filings 09/01/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/30/2006
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 08/18/2006
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 08/15/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/14/2006
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 08/14/2006
Soligenix, Inc. (SNGX) - 25-NSE SEC Filings 07/06/2006
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 05/30/2006
Soligenix, Inc. (SNGX) - SB-2/A SEC Filings 05/25/2006
Soligenix, Inc. (SNGX) - 4 SEC Filings 05/16/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/15/2006
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 05/12/2006
Soligenix, Inc. (SNGX) - SB-2 SEC Filings 05/10/2006
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 04/25/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/20/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/10/2006
Soligenix, Inc. (SNGX) - 4/A SEC Filings 04/10/2006
Soligenix, Inc. (SNGX) - 4 SEC Filings 04/10/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 04/07/2006
Soligenix, Inc. (SNGX) - NT 10-K - Current report SEC Filings 04/03/2006
Soligenix, Inc. (SNGX) - 10KSB SEC Filings 03/31/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/30/2006
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 03/08/2006
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/14/2006
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 02/13/2006
Soligenix, Inc. (SNGX) - SB-2/A SEC Filings 02/10/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/06/2006
Soligenix, Inc. (SNGX) - S-1 SEC Filings 01/20/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/20/2006
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/20/2006
Soligenix, Inc. (SNGX) - 4 SEC Filings 01/12/2006
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/03/2006
Soligenix, Inc. (SNGX) - S-8 SEC Filings 12/30/2005
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 12/12/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/09/2005
Soligenix, Inc. (SNGX) - PRE 14A SEC Filings 12/02/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/29/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/14/2005
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 11/14/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/02/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/01/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 08/15/2005
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 08/15/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/13/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/16/2005
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 05/16/2005
Soligenix, Inc. (SNGX) - 3 SEC Filings 05/10/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 05/04/2005
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/06/2005
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 04/05/2005
Soligenix, Inc. (SNGX) - CORRESP SEC Filings 03/31/2005
Soligenix, Inc. (SNGX) - UPLOAD SEC Filings 03/28/2005
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 03/21/2005
Soligenix, Inc. (SNGX) - S-3/A SEC Filings 03/14/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/14/2005
Soligenix, Inc. (SNGX) - 3 SEC Filings 03/14/2005
Soligenix, Inc. (SNGX) - S-3 SEC Filings 03/11/2005
Soligenix, Inc. (SNGX) - 10KSB SEC Filings 03/11/2005
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/24/2005
Soligenix, Inc. (SNGX) - 4 SEC Filings 02/23/2005
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 02/22/2005
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/15/2005
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/14/2005
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 02/14/2005
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 02/11/2005
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/10/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/09/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 02/03/2005
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/25/2005
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 12/17/2004
Soligenix, Inc. (SNGX) - 4 SEC Filings 12/17/2004
Soligenix, Inc. (SNGX) - 3 SEC Filings 12/17/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/14/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 12/06/2004
Soligenix, Inc. (SNGX) - 3 SEC Filings 11/29/2004
Soligenix, Inc. (SNGX) - 4 SEC Filings 11/24/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/16/2004
Soligenix, Inc. (SNGX) - 4/A SEC Filings 11/16/2004
Soligenix, Inc. (SNGX) - 4 SEC Filings 11/16/2004
Soligenix, Inc. (SNGX) - 3 SEC Filings 11/16/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/15/2004
Soligenix, Inc. (SNGX) - 4 SEC Filings 11/15/2004
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 11/15/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 11/10/2004
Soligenix, Inc. (SNGX) - 3 SEC Filings 10/26/2004
Soligenix, Inc. (SNGX) - 3 SEC Filings 10/22/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 10/15/2004
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/20/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 09/16/2004
Soligenix, Inc. (SNGX) - 4 SEC Filings 09/16/2004
Soligenix, Inc. (SNGX) - S-8 SEC Filings 09/10/2004
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 08/13/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 07/13/2004
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 05/17/2004
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 04/28/2004
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 04/28/2004
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 04/16/2004
Soligenix, Inc. (SNGX) - S-3 SEC Filings 04/15/2004
Soligenix, Inc. (SNGX) - 10KSB/A SEC Filings 04/15/2004
Soligenix, Inc. (SNGX) - 10KSB SEC Filings 03/30/2004
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 03/18/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/15/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 03/04/2004
Soligenix, Inc. (SNGX) - SC 13G/A SEC Filings 02/20/2004
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 02/19/2004
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 02/13/2004
Soligenix, Inc. (SNGX) - SC 13D/A SEC Filings 02/06/2004
Soligenix, Inc. (SNGX) - 8-K - Current report SEC Filings 01/16/2004
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 11/14/2003
Soligenix, Inc. (SNGX) - SC 13G SEC Filings 11/13/2003
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 10/30/2003
Soligenix, Inc. (SNGX) - S-3 SEC Filings 10/15/2003
Soligenix, Inc. (SNGX) - 424B3 SEC Filings 08/21/2003
Soligenix, Inc. (SNGX) - 10QSB SEC Filings 08/14/2003
Soligenix, Inc. (SNGX) - REGDEX SEC Filings 08/11/2003
Soligenix, Inc. (SNGX) - DEF 14A SEC Filings 08/05/2003

Press Releases

StockPrice Release
Soligenix announces synthetic hypericin successfully manufactured at sterling pharma solutions 07/01/2025
Soligenix highlights dr. ellen kim's recent q&a and the promise of hybryte™ in ongoing clinical trials 06/06/2025
Soligenix announces recent accomplishments and first quarter 2025 financial results 05/09/2025
Positive outcome in 75% of ctcl patients treated with hybryte™ for 18 weeks 04/14/2025
Ibn initiates coverage of soligenix inc. 03/25/2025
Soligenix announces publication demonstrating civax™ booster induces rapid broad protection against covid-19 variants 03/25/2025
Soligenix announces recent accomplishments and year end 2024 financial results 03/21/2025
Hybryte™ treatment studies presented at two medical conferences in march 03/06/2025
Soligenix to present at bio ceo & investor conference 02/04/2025
Soligenix to present at upcoming investor conferences 01/16/2025
Hybryte™ expanded treatment continues to demonstrate positive outcomes in early-stage cutaneous t-cell lymphoma 01/14/2025
Soligenix initiates confirmatory phase 3 clinical trial of hybryte™ for the treatment of cutaneous t-cell lymphoma 12/16/2024
Hybryte™ clinical results demonstrate continued improvement post-treatment 12/02/2024
Soligenix announces formation of european medical advisory board for cutaneous t-cell lymphoma 11/19/2024
Soligenix to present at november 21st virtual investor summit microcap event 11/15/2024
Soligenix initiates a phase 2 clinical trial of sgx945 (dusquetide) for the treatment of behÇet's disease 11/14/2024
Soligenix announces recent accomplishments and third quarter 2024 financial results 11/08/2024
Soligenix, inc. to present at the 2024 thinkequity conference 10/24/2024
Soligenix, inc. to present at the 2024 thinkequity conference 10/24/2024
Soligenix receives hong kong patent for improved production of synthetic hypericin 10/22/2024
Soligenix invited to present at upcoming investor conferences 10/16/2024
Hybryte™ expanded treatment results to be presented at the european organisation for research and treatment of cancer conference 10/07/2024
Soligenix announces partnership with sterling pharma solutions 10/03/2024
Nova minerals and soligenix interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 09/20/2024
Join soligenix's exclusive live investor webinar and q&a session on september 18, 2024 09/16/2024
Soligenix receives european patent for improved production of synthetic hypericin 09/03/2024
Soligenix and american resources interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 08/16/2024
Soligenix announces recent accomplishments and second quarter 2024 financial results 08/09/2024
Prism marketview features q&a with dr. ellen kim: soligenix's hybryte™— lighting the way towards commercial success with promising flash study results 07/15/2024
Expanded hybryte™ treatment demonstrating positive outcomes in early-stage cutaneous t-cell lymphoma 07/09/2024
Soligenix announces positive clinical results from a comparative study evaluating hybryte™ against valchlor® in the treatment of cutaneous t-cell lymphoma 06/25/2024
A comparison of vaccine technologies to be presented at the asm microbe conference 06/14/2024
Soligenix and sharps technology interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 06/07/2024
Soligenix announces reverse stock split 05/31/2024
Soligenix encourages stockholders to vote their shares at the annual meeting 05/29/2024
Soligenix, inc. announces adjournment of annual meeting, information for reconvened annual meeting 05/24/2024
Soligenix encourages stockholders to vote "for" reverse stock split 05/23/2024
Suvax™ and marvax™ thermostable vaccine platform to be presented at the vaccine technology ix conference 05/21/2024
Soligenix encourages stockholders to vote prior to annual meeting 05/20/2024
Positive clinical results from hybryte™ compatibility study in the treatment of cutaneous t-cell lymphoma published in jeadv clinical practice 05/16/2024
Soligenix announces recent accomplishments and first quarter 2024 financial results 05/10/2024
Soligenix to present at upcoming conferences 05/06/2024
Soligenix extends patent protection for its filovirus vaccine platform to the united kingdom and south africa 04/25/2024
Soligenix announces pricing of $4.75 million public offering 04/18/2024
Fda grants soligenix orphan drug designation for the prevention and post-exposure prophylaxis against marburg marburgvirus infection 04/15/2024
Fda grants soligenix orphan drug designation for the prevention and post-exposure prophylaxis against sudan ebolavirus infection 04/11/2024
Soligenix announces agreement on the design of a second confirmatory placebo-controlled trial for hybryte™ with the european medicines agency 04/03/2024
Soligenix announces recent accomplishments and year end 2023 financial results 03/15/2024
Soligenix announces formation of behÇet's disease medical advisory board 02/08/2024
Soligenix and mobilicom interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 01/26/2024
Soligenix to present at the microcap conference 01/25/2024
Fda grants soligenix "fast track" designation for dusquetide in the treatment of oral lesions of behÇet's disease 01/08/2024
Soligenix announces top-line results of the phase 2a study of sgx302 (synthetic hypericin) in patients with mild-to-moderate psoriasis 01/04/2024
Soligenix announces publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses 01/02/2024
"hybryte™ use in early-stage cutaneous t-cell lymphoma" published in frontiers in drug discovery 12/01/2023
Soligenix receives fda ind clearance for phase 2 clinical trial of dusquetide in the treatment of aphthous ulcers in behÇet's disease 11/30/2023
Soligenix, inc. announces adjournment of annual meeting, information for reconvened annual meeting 11/17/2023
Soligenix announces recent accomplishments and third quarter 2023 financial results 11/13/2023
Soligenix, inc. announces adjournment of annual meeting, information for reconvened annual meeting 10/20/2023
Asp isotopes and soligenix interviews to air on the redchip small stocks big money(r) show on bloomberg tv 10/20/2023
Soligenix to present at the thinkequity conference 10/16/2023
Spi energy and soligenix interviews to air on the redchip small stocks big money(r) show on bloomberg tv 10/13/2023
Knightscope, soligenix, and genetic technologies interviews to air on the redchip small stocks big money(r) show on bloomberg tv 10/06/2023
Soligenix announces achievement of two-year stability with bivalent and trivalent thermostabilized filovirus vaccines when stored at high temperatures 09/25/2023
Soligenix, inc. announces adjournment of annual meeting, information for reconvened annual meeting and additional proposal to be considered by stockholders 09/22/2023
Soligenix announces recent accomplishments and second quarter 2023 financial results 08/21/2023
Biovie and soligenix interviews to air on the redchip money report(r) on bloomberg tv 08/11/2023
Hybryte™ expanded treatment trial in cutaneous t-cell lymphoma opens enrollment 08/10/2023
Soligenix announces expansion of sgx302 (synthetic hypericin) phase 2a study in mild-to-moderate psoriasis 07/11/2023
Soligenix, and graphex group interviews to air on bloomberg tv on the redchip money report(r) 06/02/2023
Soligenix announces scheduling of type a meeting with the u.s. fda to review proposed study design for a second phase 3 study evaluating hybryte™ in the treatment of cutaneous t-cell lymphoma 05/11/2023
Soligenix announces pricing of $8.5 million public offering 05/05/2023
Soligenix announces positive clinical results from compatibility study of hybryte™ in the treatment of cutaneous t-cell lymphoma 05/04/2023
Soligenix announces appointment of timothy r. cotÉ, m.d. 05/03/2023
Soligenix enters into exclusive option agreement with silk road therapeutics for rights to topical pentoxifylline designed to treat behÇet's disease 05/01/2023
Soligenix submits type a meeting request to u.s. fda to review proposed study design for a second phase 3 study evaluating hybryte™ in the treatment of cutaneous t-cell lymphoma 04/24/2023
Soligenix provides regulatory update on hybryte™ 04/14/2023
Soligenix receives usan approval for "hypericin sodium" as nonproprietary name for novel active ingredient in hybryte™ and sgx302 04/05/2023
Soligenix announces scheduling of type a meeting with the u.s. fda for hybryte™ new drug application in the treatment of cutaneous t-cell lymphoma 04/03/2023
Soligenix announces recent accomplishments and year-end 2022 financial results 03/31/2023
Soligenix submits type a meeting request to u.s. fda for hybryte™ new drug application in the treatment of cutaneous t-cell lymphoma 03/09/2023
Soligenix receives refusal to file letter from u.s. fda for hybryte™ new drug application in the treatment of cutaneous t-cell lymphoma 02/14/2023
Soligenix invited to present at the virtual investor summit event 01/19/2023
Soligenix announces distribution of series d preferred stock to holders of its common stock 12/23/2022
Soligenix announces publication demonstrating positive correlates of protection with rivax® in non-human primate survival after ricin challenge 12/20/2022
Soligenix initiates phase 2 clinical trial of sgx302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis 12/19/2022
Soligenix announces submission of new drug application to the fda for hybryte™ in the treatment of cutaneous t-cell lymphoma 12/15/2022
Soligenix to receive $1.2 m in non-dilutive funding through new jersey technology business tax certificate transfer program 11/15/2022
Investor summit group announces soligenix, inc. to present at q4 conference 11/11/2022
Soligenix announces recent accomplishments and third quarter 2022 financial results 11/10/2022
Soligenix invited to submit barda contract proposal for development of thermostabilized subunit vaccines for sudan ebola and marburg viruses 10/27/2022
Soligenix announces formation of psoriasis medical advisory board 10/25/2022
Soligenix announces adjournment of annual meeting and information for reconvened meeting 10/20/2022
Soligenix enters q4 with multiple catalysts in play 10/13/2022
Soligenix announces partial adjournment of annual meeting and information for reconvened annual meeting 09/23/2022
Fda awards $2.6 million grant for expanded study of soligenix's hybryte(tm) for ctcl 09/12/2022
U.s. food and drug administration awards $2.6 million orphan products development grant for expanded study of hybryte™ in the treatment of cutaneous t-cell lymphoma 09/06/2022
Soligenix announces recent accomplishments and second quarter 2022 financial results 08/12/2022
Soligenix receives agreement from fda on initial pediatric study plan for hybryte™ for the treatment of cutaneous t-cell lymphoma 07/27/2022
Soligenix's hybryte(tm) treatment now within reach for rare cancer patients 07/26/2022
Soligenix announces strategic partnership with serb pharmaceuticals to supply its novel ricin antigen 07/25/2022
Hybryte™ phase 3 flash study for the treatment of cutaneous t-cell lymphoma published in jama dermatology 07/20/2022
Soligenix receives fda ind clearance for phase 2 clinical trial of synthetic hypericin in the treatment of psoriasis 06/28/2022
Soligenix announces successful protection using a bivalent thermostabilized filovirus vaccine 06/23/2022
Soligenix moves forward with treatments for cutaneous t-cell lymphoma and psoriasis 06/07/2022
Key binding characteristics of dusquetide to important intracellular protein identified 06/01/2022
Soligenix receives us patent allowance for its thermostabilized vaccine platform 05/23/2022
Soligenix announces recent accomplishments and first quarter 2022 financial results 05/13/2022
Soligenix receives $1.4m in non-dilutive government funding 04/19/2022
Soligenix announces recent accomplishments and year-end 2021 financial results 03/29/2022
Soligenix covid-19 vaccine, civax™, boosts neutralizing activity against sars-cov-2, including delta and omicron 03/17/2022
Sg blocks, inc. leads round of investment for moliving, inc. 03/02/2022
Soligenix to present at the q1 virtual investor summit 03/02/2022
Soligenix, inc. to present at the q1 virtual investor summit 03/01/2022
Soligenix to present at the 2022 bio ceo & investor conference 02/08/2022
Soligenix corporate update includes nda plans for hybryte(tm) 01/12/2022
Soligenix corporate update letter - key highlights and upcoming catalysts 01/10/2022
Soligenix to present at upcoming investor conferences 01/06/2022
Dusquetide demonstrates positive anti-tumor efficacy in multiple nonclinical animal studies 01/04/2022
Soligenix announces successful protection using a bivalent thermostabilized filovirus vaccine 12/02/2021
Soligenix announces recent accomplishments and third quarter 2021 financial results 11/12/2021
Soligenix granted pediatric investigational plan waiver for hybryte™ in ctcl in the united kingdom 11/08/2021
Soligenix announces publication demonstrating enduring protection of its thermostable rivax® vaccine 11/04/2021
Thermostable vaccine technology platform to be presented at the 6th international conference on vaccines research and development 11/01/2021
Highlights and insights into soligenix 10/13/2021
Hybryte™ flash study selected as a 'top poster' winner for presentation at the national organization for rare disorders' rare diseases and orphan products breakthrough summit 10/12/2021
Soligenix announces accelerated publication demonstrating efficacy and broad neutralizing activity of its covid-19 vaccine in non-human primates 09/28/2021
Soligenix invited to present at the cantor fitzgerald global healthcare conference 09/27/2021
Soligenix to advance synthetic hypericin development in psoriasis 09/16/2021
Fda grants soligenix orphan drug designation for the treatment of t-cell lymphoma 09/09/2021
Soligenix: developing tools to tackle the next potential pandemic; pcg digital biotech watch review 08/24/2021
Soligenix announces publication demonstrating successful formulation and heat stabilization of filovirus vaccine platform for ebola and marburg virus diseases 08/23/2021
Soligenix announces positive preclinical data with multiple heat stable filovirus vaccine candidates 08/18/2021
Soligenix announces recent accomplishments and second quarter 2021 financial results 08/13/2021
Hybryte(tm): addressing an unmet need for rare lymphoma 07/22/2021
Offering new hope for a rare form of non-hodgkin's lymphoma: a discussion with dr. ellen kim on hybryte(tm) from soligenix 07/06/2021
Hybryte™ positive pivotal phase 3 flash study selected for presentation at the united states cutaneous lymphoma consortium (usclc) annual meeting 06/22/2021
Soligenix receives pediatric investigational plan waiver for hybryte™ in ctcl from the european medicines agency 06/10/2021
Soligenix receives $865,000 in non-dilutive funding through new jersey technology business tax certificate transfer program 06/09/2021
Shining a light on soligenix's hybryte(tm) growth opportunity 06/03/2021
Soligenix receives japanese patent for improved production of synthetic hypericin composition 05/20/2021
Soligenix announces recent accomplishments and first quarter 2021 financial results 05/17/2021
Hybryte™ awarded innovation passport in the united kingdom 05/10/2021
Broad efficacy and improved safety profile of hybryte™ presented at society for investigative dermatology virtual meeting 05/04/2021
Soligenix presents at the national foundation for infectious diseases annual conference on vaccinology research 04/28/2021
Hybryte™ expanded efficacy and safety data presented at the american academy of dermatology meeting 04/26/2021
Soligenix announces presentations at prominent scientific conferences 04/13/2021
Soligenix receives conditional fda acceptance of proposed brand name hybryte™ for sgx301 in ctcl 04/07/2021
Soligenix announces recent accomplishments and year-end 2020 financial results 03/30/2021
Soligenix anticipated to achieve multiple milestones in 2021 03/16/2021
Soligenix to receive $865,000 in non-dilutive funding through new jersey technology business tax certificate transfer program 03/09/2021
Soligenix is ready for commercialization of sgx301 (hybryte(tm)); fda has approval process on fast track 02/23/2021
Soligenix's upcoming catalysts highlight growth potential as it sheds light on its commercialization of sgx301 02/09/2021
Soligenix receives hong kong patent for therapeutic use of synthetic hypericin to treat cutaneous t-cell lymphoma 02/01/2021
Soligenix poised to announce us commercialization plans of sgx301 in the treatment of cutaneous t-cell lymphoma 01/25/2021
Soligenix announces investor webcast event: u.s. commercialization of sgx301 in the treatment of cutaneous t-cell lymphoma 01/19/2021
Soligenix announces $1.5 million nih small business innovation research award advancing covid-19 vaccine development 12/28/2020
Soligenix announces topline results from its phase 3 clinical trial of sgx942 for the treatment of oral mucositis in head and neck cancer patients 12/22/2020
Soligenix, inc. covid-19 vaccine candidate, civax, could be a more viable alternative to moderna and pfizer 12/09/2020
Soligenix announces recent accomplishments and third quarter 2020 financial results 11/12/2020
Soligenix says co and fbr entered into amendment no. 1 to at market issuance sales agreement 08/28/2020
Soligenix announces second quarter 2020 financial results 08/14/2020
Soligenix inc says negative impact of pandemic on co's studies was much less significant than initially anticipated 07/20/2020
Soligenix inc files for mixed shelf of upto $50 million 07/17/2020
Soligenix announces recent accomplishments and q1 2020 financial results 05/15/2020
Soligenix announces positive top-line results for its pivotal phase 3 flash trial evaluating sgx301 in treatment of cutaneous t-cell lymphoma 03/19/2020
Fda grants soligenix "fast track" designation for rivax in the prevention of ricin poisoning 02/13/2020
Fda grants soligenix "fast track" designation for rivax in the prevention of ricin poisoning 02/12/2020
Soligenix initiates clinical trial of its heat stable ricin toxin vaccine 12/12/2019
Soligenix completes enrollment in its pivotal phase 3 clinical trial of sgx301 in the treatment of cutaneous t-cell lymphoma 12/02/2019
Soligenix, inc. presents at pcg spotlight series conference, nov-21-2019 02:30 pm 11/17/2019
Pcg spotlight, pcg spotlight series conference, nov 21, 2019 11/13/2019
Soligenix, inc. reports earnings results for the third quarter ended september 30, 2019 11/11/2019
National foundation for cancer research, perkins coie llp, new york oncology investor conference, nov 12, 2019 through nov 13, 2019 11/05/2019
Soligenix receives us patent for improved production of synthetic hypericin composition 10/23/2019
Soligenix, inc. presents at 5th annual dawson james small cap growth conference, oct-28-2019 10/20/2019
Soligenix receives non-compliance notice from nasdaq 10/17/2019
Soligenix, inc. presents at bio-europe 25th annual international partnering conference, nov-12-2019 11:45 am 10/14/2019
Nai interactive ltd., 20th annual gcff investor conference, oct 05, 2019 10/02/2019

More Headlines

News
Soligenix to Present at BIO CEO & Investor Conference PRINCETON, N.J. , Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the BIO CEO & Investor Conference. 02/04/2025
Soligenix to Present at Upcoming Investor Conferences PRINCETON, N.J. , Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. 01/16/2025
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). 01/14/2025
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma FLASH 2 Study opens patient enrollment PRINCETON, N.J. , Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). 12/16/2024
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol HPN-CTCL-04) comparing HyBryte™ (synthetic hypericin) to Valchlor® (mechlorethamine) has demonstrated continued improvement in HyBryte™ treated patients and their individual lesions even after stopping treatment. 12/02/2024
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Phase 3 clinical study of HyBryte ™ in CTCL initiating in 2024 PRINCETON, N.J. , Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease. 11/19/2024
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Q4 Investor Summit and will be available for 1-on-1 meetings throughout the day. Event: Q4 Investor Summit Presentation Time: 12:00pm - 12:30pm ET Location: https://www.webcaster4.com/Webcast/Page/3075/51675 The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market. 11/15/2024
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J. , Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease. 11/14/2024
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results PRINCETON, N.J. , Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2024. 11/08/2024
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference Princeton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc. 10/24/2024
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. 10/24/2024
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". 10/22/2024
Soligenix Invited to Present at Upcoming Investor Conferences PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will be providing a corporate update at the upcoming investor conferences on the dates below. 10/16/2024
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses PRINCETON, N.J. , Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two of its lead investigators are presenting findings from recent additional, supportive trials with HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). 10/07/2024
Soligenix Announces Partnership with Sterling Pharma Solutions U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J. , Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has established a partnership agreement with Sterling Pharma Solutions (Sterling) to optimize and implement a commercially viable, scalable production technology for synthetic hypericin. 10/03/2024
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (Nasdaq:NVA) and Soligenix Inc. (Nasdaq:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). 09/20/2024
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 PRINCETON, N.J. , Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024, at 4:15 p.m. 09/16/2024
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". 09/03/2024
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). 08/16/2024
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results PRINCETON, N.J. , Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024. 08/09/2024
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results 07/15/2024
Uncover Why This Pharma Stock Jumped 400% on Study Update Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%. 07/10/2024
5 Investors Betting Big on Soligenix (SNGX) Stock Shares of Soligenix (NASDAQ: SNGX ) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage cutaneous T-cell lymphoma (CTCL). 07/09/2024
Crude Oil Down 1%; Soligenix Shares Surge U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. 07/09/2024
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro. 07/09/2024
Why Is Soligenix (SNGX) Stock Up 296% Today? Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Tuesday following positive data from the late-stage biopharmaceutical company's extended HyBryte treatment. This data interim data comes from a 12-month study testing HyBryte as a treatment for early-stage cutaneous T-cell lymphoma (CTCL). 07/09/2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). 07/09/2024
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine gel) in the treatment of cutaneous T-cell lymphoma (CTCL). 06/25/2024
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™). 06/14/2024
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). 06/07/2024
Soligenix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares. 05/31/2024
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024. 05/29/2024
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on May 23, 2024 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on April 29, 2024. 05/24/2024
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote "FOR" a Reverse Stock Split. 05/23/2024
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™). 05/21/2024
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting Annual Meeting to be held May 23, 2024 PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to participate in the upcoming Annual Meeting of Stockholders to be held virtually at 9:00AM ET on May 23, 2024. 05/20/2024
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its compatibility study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in the Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical Practice. 05/16/2024
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results PRINCETON, N.J. , May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2024. 05/10/2024
Soligenix to Present at Upcoming Conferences PRINCETON, N.J. , May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. 05/06/2024
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of intent to grant additional patents based on its patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines" in the United Kingdom and South Africa, with other international jurisdictions pending. 04/25/2024
Soligenix Announces Pricing of $4.75 Million Public Offering PRINCETON, N.J. , April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. 04/18/2024
Soligenix surges as MarVax vaccine secures Orphan Drug Designation from FDA Soligenix (NASDAQ:SNGX) shares surged more than 44% after the biopharmaceutical company won Orphan Drug Designation from US regulators for the active ingredient in its MarVax vaccine for Marburg Marburgvirus (MARV), which causes Marburg Virus Disease. The designation specifically relates to the prevention and post-exposure prophylaxis against MARV infection. 04/15/2024
Why Are Stocks Up Today? Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected. 04/15/2024
Why Is Soligenix (SNGX) Stock Up 58% Today? Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Monday after getting an orphan drug designation for the active ingredient in MarVax. This comes from the Food and Drug Administration's (FDA) Office of Orphan Products Development. 04/15/2024
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for "the prevention and post-exposure prophylaxis against MARV infection. 04/15/2024
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in SuVax™, the subunit protein vaccine of recombinantly expressed Sudan ebolavirus (SUDV) glycoprotein, for "the prevention and post-exposure prophylaxis against SUDV infection. 04/11/2024
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study PRINCETON, N.J. , April 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received agreement from the European Medicines Agency (EMA) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease. 04/03/2024
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results PRINCETON, N.J. , March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2023. 03/15/2024
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J. , Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet's Disease. 02/08/2024
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 27, at 7 p.m. Eastern Time (ET). 01/26/2024
Soligenix to Present at The Microcap Conference PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at The Microcap Conference. 01/25/2024
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease PRINCETON, N.J. , Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet's Disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA). 01/08/2024
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis Clinical Success Achieved in Second Cohort of Patients PRINCETON, N.J. , Jan. 4, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. 01/04/2024
Soligenix shares rocket as bivalent vaccine shows preclinical efficacy Soligenix (NASDAQ:SNGX) shares added almost 35% before the opening bell on Tuesday after it revealed its novel vaccine provided 100% protection against two deadly infections in non-human primate models. The company said that its single-vial bivalent vaccine demonstrated simultaneous protection against Sudan ebolavirus and Marburg Marburgvirus, two conditions for which there are no approved vaccines or therapeutics, in the preclinical evaluation. 01/02/2024
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses PRINCETON, N.J. , Jan. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections. 01/02/2024
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J. , Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that an article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma (CTCL) has been published in Frontiers in Drug Discovery. 12/01/2023
Why Is Soligenix (SNGX) Stock Up 285% Today? Soligenix (NASDAQ: SNGX ) stock is on the rise Thursday after the company got approval from the Food and Drug Administration for a Phase 2a clinical trial of SGX945. According to a press release from Soligenix, this clinical trial covers the safety and efficacy of SGX945 as a potential treatment for aphthous ulcers in Behçet's Disease. 11/30/2023
Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study results Soligenix (NASDAQ:SNGX) shares more than doubled on Thursday after the biopharmaceutical company announced positive results from a compatibility study of its investigational therapeutic HyBryte in cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. The company is developing and moving toward the potential commercialization of HyBryte (synthetic hypericin sodium) for the treatment of CTCL, a class of non-Hodgkin's lymphoma. 05/04/2023
Soligenix stock slumps as cancer drug application is knocked back Soligenix (NASDAQ:SNGX) slumped in Tuesday's early deals after revealing its cancer drug has been knocked back by the US Food and Drug Administration. The company, in a statement, told investors that it has received a Refusal to File (RTF) letter from the FDA for its HyBryte new drug application (NDA). 02/14/2023
Soligenix Invited to Present at the Virtual Investor Summit Event Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Virtual Investor Summit on January 26, 2023. 01/19/2023
7 Stocks to Add to Your 10x Watchlist There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfolio. 12/16/2022
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit live in NYC at the Sheraton Times Square. Jonathan Guarino, the Company's Senior Vice President and Chief Financial Officer, will be presenting a Company update and attend 1x1 meetings. During the presentation Mr. 11/11/2022
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma Soligenix is an underfollowed biotech company trading at a $20 million market cap. The company is about to file an NDA for HyBryte, which I expect to become a first-in-class treatment in cutaneous T-cell lymphoma. 10/05/2022
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the American Medical Association (JAMA) Dermatology. "The peer-reviewed publication. 07/20/2022
Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants Soligenix Inc (NASDAQ: SNGX) announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs). The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including. 03/17/2022
Soligenix to Present at the Q1 Virtual Investor Summit PRINCETON, N.J., March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, has been invited to attend the Q1 Virtual Investor Summit. 03/02/2022
Soligenix, Inc. to Present at the Q1 Virtual Investor Summit Princeton, New Jersey--(Newsfile Corp. - March 1, 2022) - Soligenix, Inc. (NASDAQ: SNGX) today announced that Jonathan Guarino, Senior Vice President & Chief Financial Officer will be attending the Q1 Virtual Investor Summit. During the presentation, Soligenix's Senior Vice President & Chief Financial Officer, Jonathan Guarino, will review the Company's robust pipeline and highlight upcoming potential value drivers, including an NDA filing to the FDA later this year. The presentation will be webcast and an... 03/01/2022
Soligenix to Present at the 2022 BIO CEO & Investor Conference PRINCETON, N.J., Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. 02/08/2022
Soligenix to Present at Upcoming Investor Conferences PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below. 01/06/2022
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022 In an SEC filing, Soligenix Inc (NASDAQ: SNGX) disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related disruptions resulting in delays by the commercial active pharmaceutical ingredient manufacturer, the Company cannot provide the pre-requisite accrued stability data required to file the application. 11/01/2021
Highlights and Insights into Soligenix Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized VaccinesNew York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (NASDAQ: SNGX), spoke about the latest developments with their synthetic hypericin topical treatment HyBryte™ and the Company's ongoing research and development of thermostabilized vaccine candidates for filoviruses and COVID-19. The interview took place at the Cantor Fitzgerald Global Health Care Conference,... 10/13/2021
HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their poster abstract was selected as a "top abstract winner" and has been accepted for display and presentation at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit to be held virtually on October 18-19, 2021. 10/12/2021
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. 09/28/2021
Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference PRINCETON, N.J., Sept. 27, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. 09/27/2021
Soligenix To Test Synthetic Hypericin In Psoriasis Patients Soligenix Inc (NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis. Related Content: Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate. 09/16/2021
Soligenix to Advance Synthetic Hypericin Development in Psoriasis PRINCETON, N.J., Sept. 16, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), as well as positive proof-of-concept (PoC) demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients, the Company will be expanding this novel therapy under the research name SGX302 into psoriasis, a large and underserved market with a significant unmet medical need. 09/16/2021
SNGX Stock: The Big FDA News Giving Biotech Penny Stock Soligenix a Boost Soligenix (SNGX) stock is roaring higher on Thursday thanks to some positive news from the U.S. Food and Drug Administration today. The post SNGX Stock: The Big FDA News Giving Biotech Penny Stock Soligenix a Boost appeared first on InvestorPlace. 09/09/2021
SNGX Stock: Why It Increased Today The stock price of Soligenix, Inc. (NASDAQ: SNGX) increased by more than 13% during intraday trading today. This is why it happened. 09/09/2021
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate The FDA has granted orphan drug designation to the active ingredient hypericin to treat T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted. "The FDA's decision to grant and expand our hypericin orphan drug designation beyond CTCL signifies an important step for Soligenix as we continue to advance the program toward NDA filing in the first half of 2022," said Christopher J. 09/09/2021
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted. 09/09/2021
Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen conditions is a simple logistical hurdle. 08/24/2021
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates. 08/23/2021
Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates Soligenix Inc (NASDAQ: SNGX) announced positive preclinical data from its filovirus vaccine candidates, including thermostabilized multivalent vaccines in a single vial platform presentation. Data from non-human primates (NHP) demonstrated efficacy. 08/18/2021
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines in a single vial platform presentation. 08/18/2021
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results PRINCETON, N.J., Aug. 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2021. 08/13/2021
HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell LymphomaNew York, New York--(Newsfile Corp. - July 22, 2021) - PCG Digital -- Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin's lymphoma that currently affects between 16,000 - 20,000 Americans, with approximately 1,000 new diagnoses each year. There is currently no FDA-approved first line treatment for CTCL, leaving clinicians and patients reliant on traditional phototherapy treatments. Soligenix (NASDAQ: SNGX), a biopharmaceutical company specializing in treatments for rare diseases, is addressing this unmet need... 07/22/2021
7 Reddit Penny Stocks to Bet On if You Have $100 to Gamble Reddit traders aren't just focused on short squeezes. Here are seven ultra-risky Reddit penny stocks that have caught their attention. 07/12/2021
Offering New Hope for a Rare Form of non-Hodgkin's Lymphoma: A Discussion with Dr. Ellen Kim on HyBryte(TM) from Soligenix New York, New York--(Newsfile Corp. - July 6, 2021) - PCG Digital -- A rare form of non-Hodgkin's lymphoma, cutaneous T-cell lymphoma (CTCL) has no current FDA-approved first-line therapies. There are roughly 3,000 new CTCL cases in the United States each year, with more than 20,000 patients living with CTCL.Small cap biotech Soligenix (Nasdaq:SNGX) is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel first in class photodynamic therapy... 07/06/2021
HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting PRINCETON, N.J., June 22, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), will present key details of HyBryte™ (hypericin ointment 0.25%) efficacy and safety profile demonstrated in the FLASH study at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting, to be held on June 26, 2021. 06/22/2021
SNGX Stock Price: Over 15% Increase Pre-Market Explanation The stock price of Soligenix, Inc. (NASDAQ: SNGX) increased by over 15% pre-market. This is why it happened. 06/10/2021
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency PRINCETON, N.J., June 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received a Pediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for HyBryte™ (SGX301 or hypericin), which has recently and successfully concluded a Phase 3, pivotal clinical study for the treatment of early stage cutaneous T-cell lymphoma (CTCL). 06/10/2021
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PRINCETON, N.J., June 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program. 06/09/2021
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic Hypericin". 05/20/2021
Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryte Soligenix Inc (NASDAQ: SNGX) shares dropped during premarket after the company said it would not pursue a rolling marketing application submission for HyBryte (SGX301). Instead, it plans to submit the NDA in the first half of 2022. 05/10/2021
HyBryte™ Awarded Innovation Passport in the United Kingdom PRINCETON, N.J., May 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that HyBryte™ (hypericin) was awarded an "Innovation Passport" for the treatment of early stage cutaneous T-cell lymphoma (CTCL) in adults under the United Kingdom's (UK's) Innovative Licensing and Access Pathway (ILAP). 05/10/2021
Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study, presented confirmatory data at the Society for Investigative Dermatology (SID) Virtual Meeting, held May 3-8, 2021. 05/04/2021
Soligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research PRINCETON, N.J., April 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Scientific Officer, Oreola Donini, PhD, delivered a presentation demonstrating the potency of the CiVax™ (COVID-19 vaccine) development program in mice and non-human primates (NHPs), at the Annual Conference on Vaccinology Research (ACVR) on April 26-27, 2021. 04/28/2021
HyBryte™ Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study, delivered a presentation at the American Academy of Dermatology (AAD) Association Virtual Meeting Experience, held April 23-25, 2021. 04/26/2021
Soligenix Announces Presentations at Prominent Scientific Conferences PRINCETON, N.J., April 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today planned conference presentations scheduled through April and May. 04/13/2021
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has conditionally accepted HyBryte™ as the proposed brand name for SGX301 (synthetic hypericin), the Company's novel first-in-class photodynamic therapy for first-line treatment of early stage cutaneous T-cell lymphoma (CTCL). 04/07/2021
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results PRINCETON, N.J., March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2020. 03/30/2021
SNGX Stock Price Increases Over 10% Pre-Market: Why It Happened The stock price of Soligenix, Inc. (NASDAQ: SNGX) has increased by over 10% pre-market. This is why it happened. 03/04/2021
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SNGX) is fast approaching a new drug application (NDA) submission and potential FDA approval for SGX301 (synthetic hypericin), a photodynamic treatment option to battle the debilitating effects of cutaneous T-Cell lymphoma (CTCL).The most recent treatment option in their rare disease pipeline, SGX301, will potentially... 02/23/2021
Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301 New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key takeaways from the commercialization Q&A: 1. Soligenix will commercialize SGX301 in the U.S.... 02/09/2021
Soligenix Poised to Announce US Commercialization Plans of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for unmet medical needs has become increasingly important as the world continues to battle through the worst pandemic in our lifetime. While the news and focus of health innovation continues to be largely on COVID-19, medical breakthroughs continue to progress across the board.Soligenix, Inc. (NASDAQ: SNGX)... 01/25/2021
Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be... 01/19/2021
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the... 12/28/2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary... 12/22/2020
Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and Pfizer New York, New York--(Newsfile Corp. - December 9, 2020) - The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 million people globally have died from the coronavirus, including over 274,000 deaths in the United States. At the same time, millions of people have lost their jobs, businesses, and other income sources. The only way to truly recover from this pandemic is... 12/09/2020
Soligenix: One Approvable Drug And Another With Phase 3 Read Out Soon - $55M Valuation Won't Last Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 for oral mucositis (“OM”) remains on track for Phase 3 results in December, and is now a call option that is not priced into the stock. 10/26/2020

Unlock

SNGX Ratings Summary

SNGX Quant Ranking